Ophthotech may get over $1 billion from eye drug deal with Novartis – Chicago Tribune (blog)

Ophthotech may get over $1 billion from eye drug deal with Novartis
Chicago Tribune (blog)
Ophthotech is testing Fovista in late-stage studies to treat wet age-related macular degeneration (AMD), in combination with standard treatments including Regeneron Pharmaceuticals Inc’s Eylea and Roche Holding AG’s Avastin and Lucentis. Ophthotech …

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment